Mizuho Securities Believes Evolus (EOLS) Still Has Room to Grow

Mizuho Securities analyst Uy Ear maintained a Buy rating on Evolus (EOLSResearch Report) today and set a price target of $15.00. The company’s shares closed last Monday at $13.11, close to its 52-week high of $14.34.

According to TipRanks.com, Ear is a 2-star analyst with an average return of -0.5% and a 44.0% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and Alkermes.

Currently, the analyst consensus on Evolus is a Strong Buy with an average price target of $15.20.

See today’s best-performing stocks on TipRanks >>

Evolus’ market cap is currently $734.8M and has a P/E ratio of -10.09.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

Read More on EOLS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More